Arcutis Biotherapeutics rises on eczema drug launch

Arcutis Biotherapeutics

22/01/2024 15:10

** Shares of drug maker Arcutis Biotherapeutics  ARQT.O 
rise 12.3% to $3.65 in early trade
    ** Co launches its seborrheic dermatitis drug, Zorvye, in
the United States 
    ** Seborrheic dermatitis is a chronic form of eczema that
causes red, itchy skin on the upper back, nose or scalp
    ** ARQT stock has fallen 77.4% in the last 12 months 

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))